AVTX

Latest SEC Filings & News for AVTX

2 most recent filings and news items mentioning AVTX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/AVTX/news?limit=20"

Pull AVTX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

EarningsAug 6, 2026Neutral

Avalo Therapeutics starts Phase 3 in 2027, cash runway extends to 2029

Avalo Therapeutics reports 2026 Q2 financials with $472.2M cash and initiates a Phase 3 HS program in 2027, driving significant investor interest in its long-acting IL-1beta pipeline.

View filing at SEC.gov →

RegulatoryJun 16, 2026Positive

Avalo Therapeutics advances AVTX-010, long-acting anti-IL-1β antibody

Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody designed for hidradenitis suppurativa and other inflammatory disorders, with IND submission planned for H1 2027. The pipeline expansion builds on positive Phase 2 data for lead

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.